OncoMatch

OncoMatch/Clinical Trials/NCT06493370

Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer

Is NCT06493370 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Intravenous ascorbic acid/vitamin C for bladder cancer.

Phase 2RecruitingUniversity of Kansas Medical CenterNCT06493370Data as of May 2026

Treatment: Intravenous ascorbic acid/vitamin CThis is a phase II, single arm, Simon two-stage design, trial, enrolling patients with cisplatin ineligible MIBC and/or those patients who decline cisplatin based NAC. Assess rates of pathologic downstaging and quality of life in MIBC cisplatin-ineligible/declined patients when IVC is added to gemcitabine-carboplatin NAC.

Check if I qualify

Extracted eligibility criteria

Cancer type

Urothelial Carcinoma

Biomarker criteria

Required: G6PD normal (normal)

Normal Glucose-6-phosphate dehydrogenase (G6PD) status

Excluded: G6PD deficiency

History of G6PD deficiency

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Lab requirements

Blood counts

Absolute Neutrophil Count >1.5K/UL (patients with benign neutropenia eligible with ANC 1000-1500 at physician discretion); Platelets >100K/UL; Hemoglobin ≥ 9 g/dL

Kidney function

Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 30 mL/min using the Cockcroft-Gault equation

Liver function

Total bilirubin ≤ 2.0 x ULN; AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN unless liver metastases are present, in which case they must be ≤ 5 x ULN

Adequate organ function, defined as follows: Absolute Neutrophil Count >1.5K/UL... Platelets >100K/UL; Hemoglobin ≥ 9 g/dL; Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 30 mL/min... Total bilirubin ≤ 2.0 x ULN; AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN unless liver metastases are present, in which case they must be ≤ 5 x ULN; Normal Glucose-6-phosphate dehydrogenase (G6PD) status

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Holden Comprehensive Cancer Center - The University of Iowa · Iowa City, Iowa
  • The University of Kansas Cancer Center · Kansas City, Kansas

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify